TSCAN THERAPEUTICS INC
TCRX · NASDAQ
Updated at 2026-10-14 09:27:48
- Today's High
- $0.24
- Today’s Low
- $0.21
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $0.24
- Previous Close
- $0.23
- Volume
- 483.53K
- Market Cap
- $16.12M
- P/E Ratio
- --
- EPS
- $-0.90
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 830 WINTER STREET, WALTHAM, MA, UNITED STATES, 02451
- Country
- US
- Listing Date
- 2021-07-16
- Fiscal Year End
- December
- Shares Outstanding
- 65.35M
- CIK
- 0001783328
- Website
- www.tscan.com
Tscan Therapeutics Inc (TCRX) is a pioneering clinical-stage biotechnology company specializing in precision oncology through its proprietary T cell receptor (TCR) discovery platform. The firm is dedicated to developing a diverse pipeline of TCR-based therapeutics targeting specific cancer antigens, with the objective of enhancing patient outcomes across various malignancies. With a strong intellectual property portfolio and a strategic emphasis on T cell-based immunotherapies, Tscan is well-positioned to meet significant unmet medical needs in the oncology sector, standing out in a competitive and rapidly evolving market.
Financial Metrics
Revenue
2026-06-30
$1.05M
2026-03-31
$982K
2025-12-31
$2.56M
2025-09-30
$2.51M
Operating Expenses
2026-06-30
$31.54M
2026-03-31
$29.42M
2025-12-31
$26.42M
2025-09-30
$39.56M
Net Income
2026-06-30
-$30.35M
2026-03-31
-$28.66M
2025-12-31
-$22.97M
2025-09-30
-$35.71M
Net Profit Margin
2026-06-30
-2.88K%
2026-03-31
-2.91K%
2025-12-31
-895.09%
2025-09-30
-1.42K%
Earnings Per Share
2026-06-30
$-0.23
2026-03-31
$-0.22
2025-12-31
$-0.18
2025-09-30
$-0.28
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$28.96M
2026-03-31
-$27.28M
2025-12-31
-$21.55M
2025-09-30
-$34.24M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $1.05M | $982K | $2.56M | $2.51M |
| Operating Expenses | $31.54M | $29.42M | $26.42M | $39.56M |
| Net Income | -$30.35M | -$28.66M | -$22.97M | -$35.71M |
| Net Profit Margin | -2.88K% | -2.91K% | -895.09% | -1.42K% |
| Earnings Per Share | $-0.23 | $-0.22 | $-0.18 | $-0.28 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$28.96M | -$27.28M | -$21.55M | -$34.24M |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.